contrast, the Perrigo board of directors and management was nervous, as they had received support from the majority of their
investors in Israel but were alarmed at the number of index fund votes in support of the takeover.
But the heady feeling among Mylan’s board of directors and senior management was soon to turn grim. By evening,
Mylan’s position appeared to weaken when a tally of votes by the national stock clearinghouse, Deposit Trust Corporation,
showed that Mylan was short by about 18 million shares of the number of needed to gain a controlling interest in Perrigo.
better off owning shares in a combined Mylan/Perrigo company. In the end, Mylan was able to garner only 40% of Perrigo’s
outstanding common shares.
Even though Mylan had promised to make certain changes to its questionable governance practices immediately following
its acquisition of Perrigo, the declining value of its shares made the Mylan shares less attractive. Teva Pharmaceuticals bid to
acquire Mylan earlier in 2015 had inflated the value of Mylan’s shares to reflect most of the anticipated premium. Mylan was
buy Perrigo, but the latter successfully fended off Mylan eight months later. Mylan, one of the world’s largest generic drug
firms, was always facing an uphill fight to acquire Perrigo, the leading manufacturer of drugstore-brand products. Why?
Because it is difficult to acquire a firm whose board and management do not want to sell. Historically, hostile takeovers
eventually end with the target firm either relenting following the acquirer’s willingness to raise the offer price or with the
target able to find another suitor to buy it instead. However, Mylan, perhaps out of senior management’s hubris, thought it
its shareholders and that there was little Perrigo’s board and management could do due to lax antitakeover laws. While on
paper this looked like a good idea, in practice it turned out to be far more challenging.
While Perrigo could not utilize more traditional antitakeover defences which were largely prohibited by Irish takeover
law, it was able to exploit Mylan’s problematic governance practices. Mylan disclosed on October 30, 2015, less than 2
weeks before the tender period was to close, that it was under investigation by the U.S. Securities and Exchange Commission
Netherlands (for more information on inversions see Chapter 12). In another display of disregard for its shareholders,
Mylan used an obscure part of Dutch law allowing a target firm to put control of the firm into a foundation. While such
control would be temporary, it effectively allowed management to circumvent a shareholder vote on the Teva acquisition
attempt.
Perrigo’s board after repeatedly rejecting Mylan’s offer encouraged its shareholders to reject the Mylan tender offer by
2007, which dwarfed the total return to Mylan shareholders during the same time period. They argued that continuing the
firm’s current business strategy would be more lucrative than selling to Mylan.